PMC3804816_01
The mass is seen at the incision site (white arrow).
rt-2013-3-e41-g001.jpg
PMC3804816_01_rt-2013-3-e41-g001.jpg
fig001
Approximately 7 months later, she was readmitted to the clinic with complaint of a mass at the incision site (Figure 1).
A) The tumor showed papillary growth pattern with pleomorphic round-to-oval nuclei [Hematoxylin & Eosin (H&E) stain, x40]. B) Tumor tissue invading the muscular and lipomatous tissue (H&E stain, x4). C) Tumor cells were strongly positive for calretinin.
rt-2013-3-e41-g002.jpg
PMC3804816_01_rt-2013-3-e41-g002.jpg
fig002
Thyroid transcription factor (TTF)-1 and thyroglobulin immunostaining, which was performed to differentiate from thyroid papillary carcinoma because of papillary proliferation of epithelioid cells, was negative (Figure 2).
Positron-emission tomography imaging demonstrates increased FDG uptake of the mass (A: white arrow) and thickened pericardium (B: white arrow).
rt-2013-3-e41-g003.jpg
PMC3804816_01_rt-2013-3-e41-g003.jpg
fig003
Positron-emission tomography-computerized tomography (PET-CT) showed increased 18F-fluorodeoxyglucose (FDG) uptake (SUV max: 17.80) in a 53x53x76 mm lobulated mass extending to the paracardiac area of skin beneath the sternum with pericardial thickening (Figure 3).